TC
ACET icon

TAP Consulting’s Adicet Bio ACET Stock Holding History

TAP Consulting’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed – – 140
2021
Q4 		$0 Buy
+2
New +$343 ﹤0.01% 559

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

TAP Consulting's ACET Position: Q1 2022 in Review

TAP Consulting sold out of Adicet Bio (ACET) in Q1 2022, closing a stake of 2 shares.

TAP Consulting first reported a position in ACET in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 87 funds tracked by Wall St. Rank hold ACET as of Q1 2022.

  • TAP Consulting reported no remaining Adicet Bio position as of Q1 2022 after selling out during the quarter.
  • TAP Consulting sold 2 Adicet Bio shares in Q1 2022.
  • TAP Consulting first reported a position in Adicet Bio in Q4 2021 and held it in 1 quarter.
  • TAP Consulting's Adicet Bio position peaked at $0 in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.